Summary
We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clark G: Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoradenine 5′-monophosphate (NSC-312887), a new purine antimetabolite. Cancer Res 44:4183–4186, 1984
Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74:19–25, 1989
Plunkett W, Chubb S, Alexander L, Montgomery JA: Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40:2349–2355, 1980
White L, Shaddix SC, Cheng K-C, Brockman RW, Bennett LL Jr: Inhibition of ribonucleotide reductase and DNA polymerase of tumor cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate (2-F-ara-ATP). Proc Am Assoc Cancer Res 22:33, 1981
Brockman RW, Schabel FM Jr, Montgomery JA: Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. Biochem Pharmacol 26:2193–2196, 1977
Cancer facts, Office of Cancer Communications, National Cancer Institute, November, 1989
Oken MM, Creech RH, Tosmey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Amer J Clin Oncol 5:649–655, 1982
Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44–49, 1991
Chun HG, Leyland-Jones B, Cheson BD: Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9:175–188, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kilton, L.J., Benson, A.B., Greenberg, A. et al. Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. Invest New Drugs 10, 201–204 (1992). https://doi.org/10.1007/BF00877246
Issue Date:
DOI: https://doi.org/10.1007/BF00877246